Supply Chain Intelligence

Sarepta Therapeutics, Inc. Supply Chain

SRPT supply chain intelligence for Sarepta Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

SRPT ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

20Suppliers
30Customers
4Debt Items
20Related Chains

Source-Backed Evidence Depth

Sarepta Therapeutics, Inc. (SRPT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

60Total relationships
3Distinct source URLs
11High confidence
0.717Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Sarepta Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
ROCHE ROCHE 90% if we fail to supply ELEVIDYS to Roche in accordance with the terms of the Roche Agreement and the supply agreements to be entered into between the parties
ARWR Arrowhead Pharmaceuticals, Inc. 80% past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product…
ARWR Arrowhead Pharmaceuticals, Inc. 80% Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do no…
MYONEXUS-THERAPEUTICS-INC MYONEXUS-THERAPEUTICS-INC 80% As part of the consideration for the transaction, we are required to make contingent payments to the former shareholders of Myonexus upon achievement of a threshold amount of net sales of Myonexus products
ALNY Alnylam Pharmaceuticals, Inc. 72% Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the ris…
BMRN BioMarin Pharmaceutical Inc. 72% past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product…
BMRN BioMarin Pharmaceutical Inc. 72% Reciprocal relationship from BMRN graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from BMRN g…
CAPR Capricor Therapeutics, Inc. 72% Reciprocal relationship from CAPR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from CAPR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from CAPR g…
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
KROS Keros Therapeutics, Inc. 72% Reciprocal relationship from KROS graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from KROS graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from KROS g…
PEPG PepGen Inc. 72% Reciprocal relationship from PEPG graph: n our development efforts and have invested our research efforts to date in developing our EDO platform. Until May 2025, we had two product candidates in clin…
RGNX REGENXBIO Inc. 72% Reciprocal relationship from RGNX graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2…
RNA Atrium Therapeutics, Inc. 72% Reciprocal relationship from RNA graph: ss of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies; • our ability to obtain and maintai…
SLDB Solid Biosciences Inc. 72% Reciprocal relationship from SLDB graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from SLDB g…
TRDA Entrada Therapeutics, Inc. 72% Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage an…
BIOMARIN-LEIDEN-HOLDING-BV BIOMARIN-LEIDEN-HOLDING-BV 70% we executed a license agreement with BioMarin Leiden Holding BV, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, the "BioMarin Parties"), pursuant to which BioMarin Parties granted…
BIOMARIN-NEDERLANDS-BV BIOMARIN-NEDERLANDS-BV 70% we executed a license agreement with BioMarin Leiden Holding BV, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, the "BioMarin Parties"), pursuant to which BioMarin Parties granted…
BIOMARIN-TECHNOLOGIES-BV BIOMARIN-TECHNOLOGIES-BV 70% we executed a license agreement with BioMarin Leiden Holding BV, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, the "BioMarin Parties"), pursuant to which BioMarin Parties granted…
FATE Fate Therapeutics, Inc. 62% Reciprocal relationship from FATE graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from FATE graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from FATE g…
INCY Incyte Corporation 62% Reciprocal relationship from INCY graph: may receive if these drug candidates receive regulatory approval and are commercialized in the relevant territories will depend primarily on the development a…

Sarepta Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
CUSTOMER-1 CUSTOMER-1 90% For the Three Months Ended March 31, 2026 2025 Product revenues, net Customer 1 39 % 19 %
CUSTOMER-2 CUSTOMER-2 90% For the Three Months Ended March 31, 2026 2025 Product revenues, net Customer 2 20 % 12 %
ALNY Alnylam Pharmaceuticals, Inc. 72% exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues. Reimbursement of aforementioned products through our EAPs may cease to be availa…
ALNY Alnylam Pharmaceuticals, Inc. 72% Reciprocal relationship from ALNY graph: Reciprocal relationship from SRPT graph: exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues…
ARWR Arrowhead Pharmaceuticals, Inc. 72% Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR g…
ARWR Arrowhead Pharmaceuticals, Inc. 72% past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product…
BMRN BioMarin Pharmaceutical Inc. 72% Reciprocal relationship from BMRN graph: Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do no…
BMRN BioMarin Pharmaceutical Inc. 72% past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product…
CAPR Capricor Therapeutics, Inc. 72% Reciprocal relationship from CAPR graph: be engaged in other clinical trial programs for the same indication as our product candidates or may otherwise be resource constrained. We may be required to …
CPRX Catalyst Pharmaceuticals, Inc. 72% Reciprocal relationship from CPRX graph: Reciprocal relationship from SRPT graph: exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues…
CPRX Catalyst Pharmaceuticals, Inc. 72% exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues. Reimbursement of aforementioned products through our EAPs may cease to be availa…
IONS Ionis Pharmaceuticals, Inc. 72% exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues. Reimbursement of aforementioned products through our EAPs may cease to be availa…
IONS Ionis Pharmaceuticals, Inc. 72% Reciprocal relationship from IONS graph: Reciprocal relationship from SRPT graph: exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues…
KROS Keros Therapeutics, Inc. 72% Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement…
RGNX REGENXBIO Inc. 72% Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from SNYN…
SNYNF Sanofi 72% exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues. Reimbursement of aforementioned products through our EAPs may cease to be availa…
TRDA Entrada Therapeutics, Inc. 72% Reciprocal relationship from TRDA graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliv…
ANNUAL-REPORT-F-HOFFMAN-LA-ROCHE-LTD ANNUAL-REPORT-F-HOFFMAN-LA-ROCHE-LTD 62% rease overall capacity as well as further reduce risks associated with relying on a limited number of suppliers for manufacturing. Our gene therapy manufacturing capabilities have been greatly enhanc…
ARROWHEAD-COLLABORATION-AGREEMENT-SAREPTA-THERAP ARROWHEAD-COLLABORATION-AGREEMENT-SAREPTA-THERAP 62% and certain legal actions in Europe (the “Actions”) would be stopped or withdrawn as between the Settlement Parties. Specifically, the terms of the Settlement Agreement required that existing efforts…
BIIB Biogen Inc. 62% Reciprocal relationship from BIIB graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from BIIB graph: Reciprocal relationship from SRPT graph: exceed revenues historically genera…
CATALENT-MARYLAND-INC CATALENT-MARYLAND-INC 62% and certain legal actions in Europe (the “Actions”) would be stopped or withdrawn as between the Settlement Parties. Specifically, the terms of the Settlement Agreement required that existing efforts…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% launches and market acceptance of products launched; • changes in the amounts spent to research, develop, acquire, license or promote new and existing products; • results of clinical trial programs; …
DOJ-HHS-FALSE-CLAIMS-ACT-WORKING-GROUP DOJ-HHS-FALSE-CLAIMS-ACT-WORKING-GROUP 62% n addition, before we can begin to commercially manufacture and test our product candidates in third-party or our own facilities, we must obtain regulatory approval from the FDA, which includes a rev…
F-HOFFMAN-LA-ROCHE-LTD F-HOFFMAN-LA-ROCHE-LTD 62% rease overall capacity as well as further reduce risks associated with relying on a limited number of suppliers for manufacturing. Our gene therapy manufacturing capabilities have been greatly enhanc…
MYONEXUS-THERAPEUTICS-INC MYONEXUS-THERAPEUTICS-INC 62% rease overall capacity as well as further reduce risks associated with relying on a limited number of suppliers for manufacturing. Our gene therapy manufacturing capabilities have been greatly enhanc…
NATIONWIDE-ARROWHEAD-PHARMACEUTICALS-INC NATIONWIDE-ARROWHEAD-PHARMACEUTICALS-INC 62% and certain legal actions in Europe (the “Actions”) would be stopped or withdrawn as between the Settlement Parties. Specifically, the terms of the Settlement Agreement required that existing efforts…
NIPPON-SHINYAKU-CO-LTD NIPPON-SHINYAKU-CO-LTD 62% Patent asserted by Regenx. Plaintiffs seek injunctive relief, a judgment of infringement and willful infringement, damages that are no less than a reasonable royalty (including treble damages), attor…
NS-PHARMA-INC NS-PHARMA-INC 62% Patent asserted by Regenx. Plaintiffs seek injunctive relief, a judgment of infringement and willful infringement, damages that are no less than a reasonable royalty (including treble damages), attor…
ONO-PHARMACEUTICALS-IONIS-PHARMACEUTICALS-INC ONO-PHARMACEUTICALS-IONIS-PHARMACEUTICALS-INC 62% exceed revenues historically generated from sales through our EAP, especially in light of current geopolitical issues. Reimbursement of aforementioned products through our EAPs may cease to be availa…

Sarepta Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SRPT-DEBT-SRPT-4-875-SENIOR-CONVERTIBLE-NOTES-DUE-SEPTEMBER-1-2030-2030-09-01 4.875% Senior Convertible Notes due September 1, 2030 94% 4.875 % senior convertible notes due September 1, 2030. Listed in 10-Q 2026-05-06.
SRPT-DEBT-SRPT-1-25-SENIOR-CONVERTIBLE-NOTES-DUE-SEPTEMBER-15-2027-2027-09-15 1.25% Senior Convertible Notes due September 15, 2027 94% 1.25 % senior convertible notes due September 15, 2027. Listed in 10-Q 2026-05-06.
SRPT-DEBT Debt stack $1.4M 90% Market cache reports total debt of $1.4M.
SRPT-DEBT-12741 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Sarepta Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
SRPT-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 344 tracked holders.

Sarepta Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DYN Dyne Therapeutics, Inc. 100.00 2 ['supplier']
CAPR Capricor Therapeutics, Inc. 100.00 2 ['customer', 'supplier']
BCYC Bicycle Therapeutics plc 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 1 ['customer']
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
VEEV Veeva Systems Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Sarepta Therapeutics, Inc..

Unlock full SRPT data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
SRPT
Unlock SRPT Supply Chain Data
Verified relationships include:
ROCHEROCHESupplier90%
ARWRArrowhead Pharmaceuticals, Inc.Supplier80%
CUSTOMER-1CUSTOMER-1Customer90%
CUSTOMER-2CUSTOMER-2Customer90%
+51 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →